Clofarabine
- Generic Name
- Clofarabine
- Brand Names
- Clolar, Evoltra
- Drug Type
- Small Molecule
- Chemical Formula
- C10H11ClFN5O3
- CAS Number
- 123318-82-1
- Unique Ingredient Identifier
- 762RDY0Y2H
- Background
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...
- Indication
For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
- Associated Conditions
- Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis
- Associated Therapies
- -
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT06252870
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷CHU Brest, Brest, France
🇫🇷CHU Nantes, Nantes, France
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 302
- Registration Number
- NCT05917405
- Locations
- 🇫🇷
CRLC Caen, Caen, France
🇫🇷CHU Limoges, Limoges, France
🇫🇷CHU Besançon, Besançon, France
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
- Conditions
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Malika Kapadia
- Target Recruit Count
- 1
- Registration Number
- NCT05569512
- Locations
- 🇺🇸
Helen DeVos Children's Hospital/Spectrum Health, Grand Rapids, Michigan, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
- Conditions
- Interventions
- Drug: FludarabineDrug: ClofarabineProcedure: Hematopoietic Cell TransplantationRadiation: Total-Body IrradiationDrug: TreosulfanProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Lumbar PunctureProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Biospecimen Collection
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT04994808
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Bisantrene Combination for Resistant AML
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT04989335
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT04644016
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04220008
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT04002115
- Locations
- 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT03615105
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT03615144
- Locations
- 🇺🇸
Memorial SloanKettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.